• Bausch + Lomb advanced two first-in-class eye therapies into new trials following clinical readouts already released.
• A dual-action dry-eye drop posted encouraging mid-stage results, supporting a move into Phase 3 with an earlier primary assessment.
• The study missed its main endpoint at the original timepoint, but secondary findings supported a clinically meaningful benefit versus lifitegrast alone.
• BL1332, a topical ocular pain candidate, delivered positive Phase 1b data that backed its mechanism, supporting continued development.
• Topline Phase 2 results in post-surgical pain are expected within the next few months; peak sales estimates are about $700 million and $1.4 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bausch + Lomb Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260824701843) on August 24, 2026, and is solely responsible for the information contained therein.